pharma companies: A string of biotech firms had seen their shares slump by the mid-2000s, leaving the sector with an unfavorable image, according to The Japan Times. So when Pepti Dream was first set up, its co-founders had to dig deep into their own pockets to get it up and running. When Patrick C. Reid, now managing director of Pepti Dream Inc., arrived in Japan about a decade ago, he found investors reluctant to put much money into drug startups even though the country had world-class universities and pharma companies. It took more than 10 years for investors to get over some of their previous disappointments with IPOs in the Japanese biotech industry. Pepti Dream has seen its shares which closed at 5,390 on Friday more than double over the past two years for a market value of about 2.7 billion, and partnerships with global pharma giants including Bristol-Myers Squibb Co., Novartis AG and Roche Holding AG's Genentech have helped bring in more money. But there has since been a resurgence of interest in the sector aided partly by a more nimble drug regulator and by share gains for newer companies.
(news.financializer.com). As
reported in the news.
Tagged under pharma companies, shares slump topics.